Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents A Prospective Cohort Study

L Raber; Michael Magro; GG Stefanini; B Kalesan; Ron van Domburg; Yoshinobu Onuma; P Wenaweser; Joost Daemen; B Meier; P Juni; PWJC (Patrick) Serruys; S Windecker

doi:10.1161/CIRCULATIONAHA.111.058560

Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents A Prospective Cohort Study

L Raber, Michael Magro, GG Stefanini, B Kalesan, Ron van Domburg, Yoshinobu Onuma, P Wenaweser, Joost Daemen, B Meier, P Juni, PWJC (Patrick) Serruys, S Windecker

Cardiology

Research output: Contribution to journal › Article › Academic › peer-review

320 Citations (Scopus)

Abstract

Background-Early-generation drug-eluting stents releasing sirolimus (SES) or paclitaxel (PES) are associated with increased risk of very late stent thrombosis occurring >1 year after stent implantation. It is unknown whether the risk of very late stent thrombosis persists with newer-generation everolimus-eluting stents (EES). Methods and Results-We assessed the risk of stent thrombosis in a cohort of 12 339 patients with unrestricted use of drug-eluting stents (3819 SES, 4308 PES, 4212 EES). Results are incidence rates per 100 person-years after inverse probability of treatment weighting to adjust for group differences. During follow-up of up to 4 years, the overall incidence rate of definite stent thrombosis was lower with EES (1.4 per 100 person-years) compared with SES (2.9; hazard ratio, 0.41; 95% confidence inte Conclusion-Current treatment with EES is associated with a lower risk of very late stent thrombosis compared with early-generation drug-eluting stents. (Circulation. 2012;125:1110-1121.)

Original language	Undefined/Unknown
Pages (from-to)	1110-U108
Journal	Circulation
Volume	125
Issue number	9
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.111.058560
Publication status	Published - 2012

Access to Document

10.1161/CIRCULATIONAHA.111.058560

http://hdl.handle.net/1765/68486

Cite this

Raber, L., Magro, M., Stefanini, GG., Kalesan, B., van Domburg, R., Onuma, Y., Wenaweser, P., Daemen, J., Meier, B., Juni, P., Serruys, PWJC., & Windecker, S. (2012). Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents A Prospective Cohort Study. Circulation, 125(9), 1110-U108. https://doi.org/10.1161/CIRCULATIONAHA.111.058560

@article{c953c7af79b9455bb200db972c16e056,

title = "Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents A Prospective Cohort Study",

abstract = "Background-Early-generation drug-eluting stents releasing sirolimus (SES) or paclitaxel (PES) are associated with increased risk of very late stent thrombosis occurring >1 year after stent implantation. It is unknown whether the risk of very late stent thrombosis persists with newer-generation everolimus-eluting stents (EES). Methods and Results-We assessed the risk of stent thrombosis in a cohort of 12 339 patients with unrestricted use of drug-eluting stents (3819 SES, 4308 PES, 4212 EES). Results are incidence rates per 100 person-years after inverse probability of treatment weighting to adjust for group differences. During follow-up of up to 4 years, the overall incidence rate of definite stent thrombosis was lower with EES (1.4 per 100 person-years) compared with SES (2.9; hazard ratio, 0.41; 95% confidence inte Conclusion-Current treatment with EES is associated with a lower risk of very late stent thrombosis compared with early-generation drug-eluting stents. (Circulation. 2012;125:1110-1121.)",

author = "L Raber and Michael Magro and GG Stefanini and B Kalesan and {van Domburg}, Ron and Yoshinobu Onuma and P Wenaweser and Joost Daemen and B Meier and P Juni and Serruys, {PWJC (Patrick)} and S Windecker",

year = "2012",

doi = "10.1161/CIRCULATIONAHA.111.058560",

language = "Undefined/Unknown",

volume = "125",

pages = "1110--U108",

journal = "Circulation",

issn = "0009-7322",

publisher = "Lippincott Williams & Wilkins",

number = "9",

}

Raber, L, Magro, M, Stefanini, GG, Kalesan, B, van Domburg, R, Onuma, Y, Wenaweser, P, Daemen, J, Meier, B, Juni, P, Serruys, PWJC & Windecker, S 2012, 'Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents A Prospective Cohort Study', Circulation, vol. 125, no. 9, pp. 1110-U108. https://doi.org/10.1161/CIRCULATIONAHA.111.058560

TY - JOUR

T1 - Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents A Prospective Cohort Study

AU - Raber, L

AU - Magro, Michael

AU - Stefanini, GG

AU - Kalesan, B

AU - van Domburg, Ron

AU - Onuma, Yoshinobu

AU - Wenaweser, P

AU - Daemen, Joost

AU - Meier, B

AU - Juni, P

AU - Serruys, PWJC (Patrick)

AU - Windecker, S

PY - 2012

Y1 - 2012

N2 - Background-Early-generation drug-eluting stents releasing sirolimus (SES) or paclitaxel (PES) are associated with increased risk of very late stent thrombosis occurring >1 year after stent implantation. It is unknown whether the risk of very late stent thrombosis persists with newer-generation everolimus-eluting stents (EES). Methods and Results-We assessed the risk of stent thrombosis in a cohort of 12 339 patients with unrestricted use of drug-eluting stents (3819 SES, 4308 PES, 4212 EES). Results are incidence rates per 100 person-years after inverse probability of treatment weighting to adjust for group differences. During follow-up of up to 4 years, the overall incidence rate of definite stent thrombosis was lower with EES (1.4 per 100 person-years) compared with SES (2.9; hazard ratio, 0.41; 95% confidence inte Conclusion-Current treatment with EES is associated with a lower risk of very late stent thrombosis compared with early-generation drug-eluting stents. (Circulation. 2012;125:1110-1121.)

AB - Background-Early-generation drug-eluting stents releasing sirolimus (SES) or paclitaxel (PES) are associated with increased risk of very late stent thrombosis occurring >1 year after stent implantation. It is unknown whether the risk of very late stent thrombosis persists with newer-generation everolimus-eluting stents (EES). Methods and Results-We assessed the risk of stent thrombosis in a cohort of 12 339 patients with unrestricted use of drug-eluting stents (3819 SES, 4308 PES, 4212 EES). Results are incidence rates per 100 person-years after inverse probability of treatment weighting to adjust for group differences. During follow-up of up to 4 years, the overall incidence rate of definite stent thrombosis was lower with EES (1.4 per 100 person-years) compared with SES (2.9; hazard ratio, 0.41; 95% confidence inte Conclusion-Current treatment with EES is associated with a lower risk of very late stent thrombosis compared with early-generation drug-eluting stents. (Circulation. 2012;125:1110-1121.)

U2 - 10.1161/CIRCULATIONAHA.111.058560

DO - 10.1161/CIRCULATIONAHA.111.058560

M3 - Article

VL - 125

SP - 1110-U108

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 9

ER -